Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases

被引：39

作者：

Li, Chao ^{[1
]}

Yang, Jie ^{[2
]}

Wang, Yu ^{[2
]}

Qi, Yingzi ^{[3
]}

Yang, Wenqing ^{[1
]}

Li, Yunlun ^{[1
,2
]}

机构：

[1] Shandong Univ Tradit Chinese Med, Expt Ctr, Jinan, Peoples R China

[2] Shandong Univ Tradit Chinese Med, Cardiovasc Dept, Affiliated Hosp, Jinan, Peoples R China

[3] Shandong Univ Tradit Chinese Med, Sch Hlth, Jinan, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2020年 / 11卷

基金：

中国博士后科学基金;

关键词：

Farnesoid X Receptor; cardiometabolic diseases; lipid metabolism; diabetes mellitus; obesity; FATTY LIVER-DISEASE; ENDOPLASMIC-RETICULUM STRESS; BILE-ACID METABOLISM; FXR AGONIST; CARDIOVASCULAR-DISEASE; NUCLEAR RECEPTOR; INSULIN-RESISTANCE; CHENODEOXYCHOLIC ACID; OBETICHOLIC ACID; ASYMMETRIC DIMETHYLARGININE;

D O I：

10.3389/fphar.2020.01247

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cardiometabolic diseases are characterized as a combination of multiple risk factors for cardiovascular disease (CVD) and metabolic diseases including diabetes mellitus and dyslipidemia. Cardiometabolic diseases are closely associated with cell glucose and lipid metabolism, inflammatory response and mitochondrial function. Farnesoid X Receptor (FXR), a metabolic nuclear receptor, are found to be activated by primary BAs such as chenodeoxycholic acid (CDCA), cholic acid (CA) and synthetic agonists such as obeticholic acid (OCA). FXR plays crucial roles in regulating cholesterol homeostasis, lipid metabolism, glucose metabolism, and intestinal microorganism. Recently, emerging evidence suggests that FXR agonists are functional for metabolic syndrome and cardiovascular diseases and are considered as a potential therapeutic agent. This review will discuss the pathological mechanism of cardiometabolic disease and reviews the potential mechanisms of FXR agonists in the treatment of cardiometabolic disease.

引用

页数：15

共 172 条

[41] A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia [J].

Evans, Mark J. ;

Mahaney, Paige E. ;

Borges-Marcucci, Lisa ;

Lai, KehDih ;

Wang, Shuguang ;

Krueger, Julie A. ;

Gardell, Stephen J. ;

Huard, Christine ;

Martinez, Robert ;

Vlasuk, George P. ;

Harnish, Douglas C. .

AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2009, 296 (03) :G543-G552

[42] Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance [J].

Fang, Sungsoon ;

Suh, Jae Myoung ;

Reilly, Shannon M. ;

Yu, Elizabeth ;

Osborn, Olivia ;

Lackey, Denise ;

Yoshihara, Eiji ;

Perino, Alessia ;

Jacinto, Sandra ;

Lukasheva, Yelizaveta ;

Atkins, Annette R. ;

Khvat, Alexander ;

Schnab, Bernd ;

Yu, Ruth T. ;

Brenner, David A. ;

Coulter, Sally ;

Liddle, Christopher ;

Schoonjans, Kristina ;

Olefsky, Jerrold M. ;

Saltiel, Alan R. ;

Downes, Michael ;

Evans, Ronald M. .

NATURE MEDICINE, 2015, 21 (02) :159-165

[43] Sex hormones, aging and cardiometabolic syndrome [J].

Faulkner, Jessica L. ;

de Chantemele, Eric J. Belin .

BIOLOGY OF SEX DIFFERENCES, 2019, 10 (1)

[44] Investigation around the Oxadiazole Core in the Discovery of a New Chemotype of Potent and Selective FXR Antagonists [J].

Festa, Carmen ;

Finamore, Claudia ;

Marchiano, Silvia ;

Di Leva, Francesco Saverio ;

Carino, Adriana ;

Monti, Maria Chiara ;

del Gaudio, Federica ;

Ceccacci, Sara ;

Limongelli, Vittorio ;

Zampella, Angela ;

Fiorucci, Stefano ;

De Marino, Simona .

ACS MEDICINAL CHEMISTRY LETTERS, 2019, 10 (04) :504-510

[45] Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis [J].

Fiorucci, S ;

Clerici, C ;

Antonelli, E ;

Orlandi, S ;

Goodwin, B ;

Sadeghpour, BM ;

Sabatino, G ;

Russo, G ;

Castellani, D ;

Willson, TM ;

Pruzanski, M ;

Pellicciari, R ;

Morelli, A .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (02) :604-612

[46] Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR) [J].

Flatt, Brenton ;

Martin, Richard ;

Wang, Tie-Lin ;

Mahaney, Paige ;

Murphy, Brett ;

Gu, Xiao-Hui ;

Foster, Paul ;

Li, Jiali ;

Pircher, Parinaz ;

Petrowski, Mary ;

Schulman, Ira ;

Westin, Stefan ;

Wrobel, Jay ;

Yan, Grace ;

Bischoff, Eric ;

Daige, Chris ;

Mohan, Raju .

JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (04) :904-907

[47] Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome - A summary of the evidence [J].

Ford, ES .

DIABETES CARE, 2005, 28 (07) :1769-1778

[48] Metabolic syndrome and risk of cardiovascular disease: A meta-analysis [J].

Galassi, Andrea ;

Reynolds, Kristi ;

He, Jiang .

AMERICAN JOURNAL OF MEDICINE, 2006, 119 (10) :812-819

[49] Metabolic syndrome and risk of incident cardiovascular events and death - A systematic review and meta-analysis of longitudinal studies [J].

Gami, Apoor S. ;

Witt, Brandi J. ;

Howard, Daniel E. ;

Erwin, Patricia J. ;

Gami, Lisa A. ;

Somers, Virend K. ;

Montori, Victor M. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (04) :403-414

[50] Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent [J].

Gan, Lay T. ;

Van Rooyen, Derrick M. ;

Koina, Mark E. ;

McCuskey, Robert S. ;

Teoh, Narcissus C. ;

Farrell, Geoffrey C. .

JOURNAL OF HEPATOLOGY, 2014, 61 (06) :1376-1384

← 1 2 3 4 5 6 7 8 9 10 →